Amol Kavishwar

Amol Kavishwar has an extensive background in antibody engineering and phage display, with experience in various prestigious organizations such as Neurocrine Biosciences, AbbVie, and Massachusetts General Hospital. Their research has focused on developing antibody phage-display platforms, creating systems for soluble antibody production, and working on cancer nano-therapeutics. They have also studied glycation-inactivation of complement regulatory proteins and developed monoclonal antibodies against CD59. Throughout their career, they have made significant contributions to the field of immunotherapy.